Equity
€27.9m ▲ 1.5%
Viatris GX has made a profit without a break since 2019.
Viatris GX
Lifetime
18 annual accounts with figures on one time axis, 19 filings since 2007peak €41.6m (2008)
-not published
lowest -€34.7m (2011)
€407,069▲ 2.9%
peak €28.9m (2016)
€27.9m▲ 1.5%
€3.2m▼ 15.7%
peak 90.3 FTE (2011)
-not published
Board22 names since 2007all names
2 directorsTomasz Buczek and 1 other
Owners4 names in the annual accounts
Documentsfilings and deeds
07-07-202624 days before the deadline
2025financial year
Resignation: Matthew Salzmann (director) 10-12Resignation: Vincent Verschraegen (director) 10-07Debts from €3.8m to €3.2m
Key points
from the 2025 annual accountsPayment terms
49 days to suppliers
Viatris GX pays its suppliers 35 days earlier than in 2024.
Filings
19 annual accounts since 2007
Three of the last ten came late. The 2021 accounts came latest: 72 days after the end of the period.
At the same address
5 companies
Board
1 joined · 1 left
Board changed. Latest change 10-12-2025 · 2 in office.
Position in the sector
€27.9m
More equity than 94% of companies in wholesale trade. Sector median €1.6m · 6,123 companies.
Checked score
92
Excellent
Financially stronger than 77% of medium-sized companies in wholesale trade (NACE 46)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 745 companies (NACE 46, medium-sized).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.5%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.2%▼ -0.3 percentage points vs 07-2025lowest value
09-2025: 0.2%● unchanged vs 08-2025lowest value
10-2025: 0.2%● unchanged vs 09-2025lowest value
11-2025: 0.2%● unchanged vs 10-2025lowest value
12-2025: 0.2%● unchanged vs 11-2025lowest value
01-2026: 0.2%● unchanged vs 12-2025lowest value
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 0.35
lowers risk
Founded in 2006
Size: total assets €31.1m
Figures for financial year 2025 (filed on 07-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, medium-sized). It does better than 93% of them on solvency, 99% on liquidity, 75% on profitability and 41% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit verdict
Credit of up to €2,550,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.35 (0.34 in 2024), below 1. Short-term debt is 10.2% of total assets. 10.2% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 days early
2024
34 days early
2023
34 days early
2022
19 days early
2021
72 days late
2020
18 days early
2019
22 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 11 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 7 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- Mylan Luxembourg 6 S.à r.l. 100%annual accounts 2025
- Viatris Inc consolidatesannual accounts 2020
Shares in 1 company, DOCPHARMA
Board & ownershipRecent changes
Resignation: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor) · General meeting of 18-06-2026 · Gazette deed
Resignation: Matthew Salzmann (director)
Appointment: Arun Narayan (director) · Director discharge: Matthew Salzmann · General meeting of 26-11-2025 · Gazette deed
Resignation: Vincent Verschraegen (director)
Appointment: Tomasz Buczek (director) · General meeting of 24-06-2025 · Gazette deed
Resignation: Luis Birbuet (director)
Appointment: Matthew Salzmann (director) · Director discharge: Luis Birbuet · General meeting of 06-03-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Viatris GX Hoeilaart | - | - | 89.8% | - |
| INTUITIVE SURGICAL Berchem-Sainte-Agathe | €16.6m | 3.1% | 84.2% | 36.6 |
| PORTON EUROPE Turnhout | €64.7m | 1.9% | 43.1% | 1 |
| VOLCANO EUROPE Zaventem | €43.1m | 3.4% | 65.9% | 105.6 |
| CHIESI Zaventem | €80.6m | 4.9% | 6.4% | 47.1 |
| BAXTER BELGIUM Lessines | €14.3m | 13.6% | 9.2% | 32.1 |
| SYLPHAR Sint-Martens-Latem | €25.0m | 4.6% | 78.8% | 26.7 |
These companies have the same main activity as Viatris GX: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €26m and €43m, founded between 2003 and 2010.
Official details
Source: KBO- Status
- Active since 20-12-2006Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment unit
- 2.158.221.2941560 Hoeilaart, since 29-12-2006
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Annual accounts 2025
- €31.1m▼ 0.6%
- ≈ 0 FTEestimated
- Filing
- Filed on 07-07-2026, 24 days before the end of the filing period
Insights on Viatris GX
Viatris GX has existed since 2006. Turnover fell from €29.4m in 2021 to €12,885 in 2022.
Mylan Luxembourg 6 S.à r.l. holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Viatris GX
- What is the company number of Viatris GX?
- The company number of Viatris GX is 0885.805.780. The VAT number is the same number with BE in front: BE 0885.805.780.
- Where is Viatris GX based?
- The registered office is at Terhulpsesteenweg 6A, 1560 Hoeilaart.Company details
- What does Viatris GX do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of Viatris GX?
- Viatris GX is a private limited company (BV).
- When was Viatris GX founded?
- Viatris GX was founded on 20-12-2006.
- Is Viatris GX still active?
- Yes, Viatris GX is an active enterprise in the KBO register.
- How many employees does Viatris GX have?
- Viatris GX had an average of 54.6 full-time equivalents in financial year 2021, according to the filed annual accounts.Financials
- Which joint committee does Viatris GX fall under?
- In its 2025 annual accounts, Viatris GX states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of Viatris GX?
- The annual accounts for financial year 2025 state no turnover. In financial year 2023 turnover was €0.
- Is Viatris GX profitable?
- In financial year 2025, Viatris GX made a profit of €407,069.
- Where can I find the annual accounts of Viatris GX?
- Viatris GX filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Viatris GX due?
- Viatris GX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.